title: The influence of hepatitis C virus genotypes on the outcome of liver transplantation.
abstract: BACKGROUND
  The aim of this study was to report the influence of hepatitis C virus (HCV) genotypes and HLA matches on the outcome of liver transplantation, hepatitis recurrence, and progression to cirrhosis after transplantation.
  
  
  METHODS
  HCV genotypes were determined from pretransplantation sera and/or liver explant tissues from 202 patients with HCV-related end-stage liver disease. One hundred fifty patients with known infecting genotype for whom posttransplantation biopsy specimens were available or who had normal results of liver injury tests constituted the group analyzed. Patients were followed up for up to 4.5 years. Hepatitis activity index scores at the time of disease recurrence were used to assess disease activity. Cirrhosis was diagnosed by using histological evidence. The number of HLA matches with respect to A, B, DR, and DQ loci was determined.
  
  
  RESULTS
  The rates of hepatitis recurrence were 25% and 75% at 1 year and 4 years, respectively; Kaplan-Meier survival analysis did not reveal significant differences between the infecting genotypes with respect to overall rates of survival or recurrence of hepatitis. At hepatitis recurrence, hepatitis activity index scores did not differ between the genotype groups. The distribution of infecting genotypes among the 7 patients who developed cirrhosis is reflective of pretransplantation distribution. Neither HLA site-specific nor total matches affected the rates of survival or disease recurrence.
  
  
  CONCLUSIONS
  The infecting HCV genotype had no influence on the incidence or severity of recurrent hepatitis, rate of survival, or development of cirrhosis. HLA matching does not influence transplantation outcome for HCV-related disease.
authors.affiliation: Division of Gastroenterology, T.E. Starzl Transplantation Institute, University of Pittsburgh, PA 15213-2582, USA.
authors.forename: H E
authors.initials: HE
authors.lastname: Vargas
authors.forename: T
authors.initials: T
authors.lastname: Laskus
authors.forename: L F
authors.initials: LF
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Radkowski
authors.forename: A
authors.initials: A
authors.lastname: Poutous
authors.forename: R
authors.initials: R
authors.lastname: Lee
authors.forename: J A
authors.initials: JA
authors.lastname: Demetris
authors.forename: T
authors.initials: T
authors.lastname: Gayowski
authors.forename: I R
authors.initials: IR
authors.lastname: Marino
authors.forename: N
authors.initials: N
authors.lastname: Singh
authors.forename: F
authors.initials: F
authors.lastname: Dodson
authors.forename: A
authors.initials: A
authors.lastname: Casavilla
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: J
authors.initials: J
authors.lastname: Rakela
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics*; D006650:Histocompatibility Testing; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis; D016031:Liver Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome